Cargando…
NCL1, A Highly Selective Lysine-Specific Demethylase 1 Inhibitor, Suppresses Castration-Resistant Prostate Cancer Growth via Regulation of Apoptosis and Autophagy
Recent studies have shown that epigenetic alterations lead to oncogenic activation, thus indicating that these are therapeutic targets. Herein, we analyzed the efficacy and therapeutic potential of our developed histone lysine demethylase 1 (LSD1) inhibitor, NCL1, in castration-resistant prostate ca...
Autores principales: | Etani, Toshiki, Naiki, Taku, Naiki-Ito, Aya, Suzuki, Takayoshi, Iida, Keitaro, Nozaki, Satoshi, Kato, Hiroyuki, Nagayasu, Yuko, Suzuki, Shugo, Kawai, Noriyasu, Yasui, Takahiro, Takahashi, Satoru |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6517972/ https://www.ncbi.nlm.nih.gov/pubmed/30935141 http://dx.doi.org/10.3390/jcm8040442 |
Ejemplares similares
-
NCL1, a highly selective lysine-specific demethylase 1 inhibitor, suppresses prostate cancer without adverse effect
por: Etani, Toshiki, et al.
Publicado: (2014) -
Selective lysine‐specific demethylase 1 inhibitor, NCL1, could cause testicular toxicity via the regulation of apoptosis
por: Nozaki, Satoshi, et al.
Publicado: (2020) -
Luteolin suppresses bladder cancer growth via regulation of mechanistic target of rapamycin pathway
por: Iida, Keitaro, et al.
Publicado: (2020) -
GPX2 promotes development of bladder cancer with squamous cell differentiation through the control of apoptosis
por: Naiki, Taku, et al.
Publicado: (2018) -
Recruitment of miR-8080 by luteolin inhibits androgen receptor splice variant 7 expression in castration-resistant prostate cancer
por: Naiki-Ito, Aya, et al.
Publicado: (2020)